MedTrace Logo

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

NCT03235024 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2022-10-10

Study results available
· View outcomes & findings →

Summary

This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 28 days vs vehicle application on treatment of mild to moderate AD

Conditions

  • Atopic Dermatitis Eczema

Interventions

BIOLOGICAL

B244

B244 suspension

BIOLOGICAL

Vehicle

Vehicle suspension

Sponsors & Collaborators

  • Veristat, Inc.

    collaborator OTHER

  • AOBiome LLC

    lead INDUSTRY

Principal Investigators

  • Judith Ng-Cashin, MD · Chief Medical Officer

  • Spiros Jamas, ScD · AOBiome LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2019-02-27
Completion
2019-03-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03235024 on ClinicalTrials.gov